Mechanism of Action of Terlipressin
Terlipressin is a synthetic vasopressin analog that functions both as a prodrug for lysine-vasopressin and as a direct vasopressin receptor agonist, primarily targeting V1 receptors to cause splanchnic vasoconstriction, thereby reversing the pathologic vasodilation responsible for hepatorenal syndrome. 1
Primary Mechanism
Terlipressin exhibits dual pharmacologic activity:
- Direct V1 receptor agonism: Terlipressin has twice the selectivity for vasopressin V1 receptors compared to V2 receptors, though it binds with micromolar affinity (approximately 120-fold lower than its active metabolite) 1, 2
- Prodrug conversion: Tissue peptidases cleave the N-terminal glycyl residues of terlipressin, releasing the pharmacologically active metabolite lysine-vasopressin (LVP), which is a full V1 agonist 1
Hemodynamic Effects in Hepatorenal Syndrome
The therapeutic benefit in HRS-AKI occurs through splanchnic vasoconstriction:
- Reduces portal hypertension by constricting dilated splanchnic blood vessels, decreasing blood flow into the portal vein and through portosystemic shunts 3, 4
- Increases effective arterial volume and mean arterial pressure (MAP), with maximum MAP increases of approximately 16.2 mmHg occurring 1.2-2 hours post-dose 1
- Improves renal perfusion by counterbalancing the pathologic splanchnic arterial vasodilation that characterizes cirrhosis, thereby restoring renal blood flow and glomerular filtration rate 3, 5, 4
Receptor Pharmacology
Terlipressin demonstrates non-selective vasopressin receptor activity:
- V1A receptors: Acts as a partial agonist with vasoconstrictor effects on vascular smooth muscle 2, 6
- V2 receptors: Functions as a full agonist, which may contribute to antidiuretic effects and potential water retention 2, 6
- V1B receptors: Also exhibits full agonist activity at these receptors 2
The in vivo response results from both the partial V1 agonist activity of terlipressin itself and the full V1 agonist activity of its metabolite LVP 6
Pharmacodynamic Timeline
Hemodynamic effects occur rapidly and are sustained:
- Onset: Increases in blood pressure and decreases in heart rate (approximately 10.6 beats/minute reduction) are evident within 5 minutes of administration 1
- Duration: Effects are maintained for at least 6 hours after dosing, supporting the every-6-hour dosing regimen 1
- Peak effect: Maximum hemodynamic changes occur 1.2-2 hours post-dose 1
Clinical Implications of Mechanism
The vasoconstrictor mechanism underlies both therapeutic benefits and adverse effects:
- Therapeutic: A sustained MAP increase of 5-10 mmHg with treatment is associated with response to terlipressin in HRS-AKI 3
- Adverse effects: Vasoconstriction can cause ischemic complications including cardiac, splanchnic, and digital ischemia, occurring in approximately 4.5% of patients 3
- Respiratory effects: The mechanism may contribute to respiratory failure (15.5% incidence), particularly in patients with baseline elevated MAP or concomitant organ failure 3
Metabolism and Elimination
Terlipressin undergoes predictable enzymatic conversion:
- Metabolism: Ubiquitous tissue peptidases cleave terlipressin to release LVP; this process is not affected by disease state or drug interactions due to the widespread distribution of peptidases 1
- Half-life: Terminal half-life is 0.9 hours for terlipressin and 3.0 hours for lysine-vasopressin 1
- Excretion: Less than 1% is excreted unchanged 1